Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Updates in Relapsed/Refractory Myeloma

January 29th 2021

Updates in Multiple Myeloma in the Frontline Setting

January 29th 2021

Dr. Callander on the Expanding Role of Belantamab Mafodotin in Multiple Myeloma

January 28th 2021

Natalie S. Callander, MD, discusses the expanding role of belantamab mafodotin-blmf in multiple myeloma.

RRMM: Incorporating INN Melphalan Flufenamide Into Clinical Practice

January 28th 2021

RRMM: INN Melphalan Flufenamide After Alkylator Therapy

January 28th 2021

Dr. Kumar on Treatment Selection Considerations in Multiple Myeloma

January 27th 2021

Shaji K. Kumar, MD, discusses treatment selection considerations in multiple myeloma.

Role of Therapeutic Intervention in SMM

January 27th 2021

Overview of Smoldering Multiple Myeloma

January 27th 2021

Dr. Fonseca on the Shift Toward Frontline Quadruplet Regimens in Multiple Myeloma

January 26th 2021

Rafael Fonseca, MD, discusses the shift toward frontline quadruplet regimens in multiple myeloma.

Dr. Ailawadhi on Potential Combination Strategies in Multiple Myeloma

January 26th 2021

Sikander Ailawadhi, MD, discusses potential combination strategies with selinexor and belantamab mafodotin-blmf in multiple myeloma.

DREAMM-2 Trial Regimen: Safety Updates and Dose Delay

January 25th 2021

Management of Ocular Events From DREAMM-2 Regimen

January 25th 2021

Dr. Schmidt on the Utilization of Bispecific Antibodies in Myeloma

January 22nd 2021

Timothy M. Schmidt, MD, discusses the utilization of bispecific antibodies in myeloma.

Dr. Callander on Selecting a Frontline Treatment Strategy in Multiple Myeloma

January 22nd 2021

Natalie S. Callander, MD, discusses selecting a frontline treatment strategy for patients with multiple myeloma.

Determining How to Incorporate MRD Into Care Decisions for Myeloma

January 22nd 2021

Kathleen A. Dorritie, MD, details the utility of minimal residual disease in multiple trials in the multiple myeloma space.

PANORAMA 3 Study Resets Expectations for Panobinostat in Multiple Myeloma

January 21st 2021

Andrew Spencer, MD, MBBS, FRACP, FRCPA discusses the significance of the PANORAMA 3 study in multiple myeloma.

Dr. Lin on the Importance of Developing non-BCMA–Targeting Agents in Myeloma

January 20th 2021

Yi Lin, MD, PhD, discusses the importance of developing non-BCMA–targeting agents in multiple myeloma.

Dr. Kumar on the Emergence of MRD Negativity as an End Point in Multiple Myeloma

January 20th 2021

Shaji K. Kumar, MD, discusses the emergence of minimal residual disease negativity as a surrogate end point in relapsed/refractory multiple myeloma.

First BCMA-Targeting Therapy Debuts in Multiple Myeloma

January 20th 2021

Sagar Lonial, MD, discussed key facets of belantamab mafodotin and potential next steps.

Dr. Hari on Treatment Considerations for Relapsed/Refractory Multiple Myeloma

January 19th 2021

Parameswaran Hari, MD, MRCP, discusses treatment strategies for patients with relapsed/refractory multiple myeloma.